T1	Intervention 203 264	simple validated high-performance liquid chromatography (HPLC
T2	Intervention 771 795	Under fasting conditions
T3	Intervention 847 989	allocated to receive a single oral dose of either one FDC tablet or co-administration of two separate diflunisal and naproxen marketed tablets
T4	Intervention 991 1139	Plasma samples were obtained over a 72-h interval and analyzed for diflunisal and naproxen by reversed phase liquid chromatography with UV detection
